Abstract: Tetrapeptide L-alanyl-L-glutamyl-L-asparagyl-L-proline of the general formula L-Ala-L-Glu-Asp-L-Pro is proposed as a biologically active compound stimulating the functional activity of neurones. The application of L-Ala-L-Glu-L-Asp-L-Pro tetrapeptide in medicine is proposed for the preparation of a drug stimulating the functional activity of neurones. There is proposed a pharmacological agent, which contains as its active base an effective amount of L-Ala-L-Glu-L-Asp-L-Pro tetrapeptide for its salts of the amino acid group (acetate, hydrochloride, oxalate) or its salts of carboxyl groups (the salts of sodium, potassium, calcium, lithium, zinc, magnesium, and also the salts of organic and inorganic cations-ammonium, triethylammonium). The agent is proposed for parenteral, intranasal and oral administration.

Abstract: Methods of treatment of subjects for decreasing cell mediated autoimmunity or humoral autoimmunity by administering an R′-Glu-Trp-R″ pharmaceutical preparation useful in subjects having autoimmune diseases.

Abstract: Methods of treatment of subjects for decreasing cell mediated autoimmunity or humoral autoimmunity by administering an R′-Glu-Trp-R″ pharmaceutical preparation useful in subjects having autoimmune diseases.

Abstract: Pharmaceutical compositions and methods are provided for the therapy of immunodeficient, immunodepressed or hyperactive immune states and for the prevention and treatment of opportunistic infections in such states comprising administering to a subject a pharmaceutically acceptable composition comprising as an active ingredient peptides having the formula R′-L-Glx-L-Glx-L-Lys-R″ and/or their pharmaceutically acceptable salts; wherein Glx is Gln or Glu.

Abstract: Methods of treatment of subjects for decreasing cell mediated autoimmunity or humoral autoimmunity by administering an R′-Glu-Trp-R″ pharmaceutical preparation useful in subjects having autoimmune diseases.

Abstract: Pharmaceutical compositions and methods are provided for the therapy of immunodeficient, immunodepressed or hyperactive immune states and for the prevention and treatment of opportunistic infections in such states comprising administering to a subject a pharmaceutically acceptable composition comprising as an active ingredient peptides having the formula R′-L-Glx-L-Glx-L-Lys-R″ and/or their pharmaceutically acceptable salts; wherein Glx is Gln or Glu.

Abstract: This invention provides peptides of the formula R'-Glx-Glx-Lys-R" in which Glx is Glu or Gln. In particular, this invention provides the peptides Thr-Ala-Glu-Glu-Lys and Thr-Pro-Glu-Glu-Lys. This invention also provides pharmaceutical compositions comprising these peptides. The peptides of this invention are useful for immunomodulation.

Abstract: This invention provides methods of modulating the immune system by administering peptides of the formula R'-Glx-Glx-Lys-R" (SEQ ID NO:1) in which Glx is Glu or Gln. In particular, this invention provides the use of peptides Thr-Ala-Glu-Glu-Lys (SEQ ID NO:34) and Thr-Pro-Glu-Glu-Lys (SEQ ID NO:33).

Abstract: Methods of treatment of subjects for decreasing cell mediated autoimmunity or humoral autoimmunity by administering an R'-Glu-Trp-R" pharmaceutical preparation useful in subjects having autoimmune diseases.

Abstract: This invention provides methods of treating purulent inflammatory diseases by administering L-Glu-L-Trp or a salt thereof.

Abstract: Methods of treatment of subjects with systemic toxicity by administering an R'-Glu-Trp-R" pharmaceutical preparation.

Abstract: A pharmaceutical preparation for the therapy of immune deficiency conditions comprising an active principle--a peptide of the structure: H-L-Glu-L-Trp-OH and a pharmaceutically acceptable vehicle.

Abstract: This invention provides methods for normalizing the numbers of lymphocytes in animals by administering the dipeptide L-Glu-L-Trp.

Abstract: A pharmaceutical preparation for the therapy of immune deficiency conditions comprising an active principle--a peptide of the structure: H-L-Glu-L-Trp-OH and a pharmaceutically acceptable vehicle.

Abstract: A pharmaceutical preparation for the therapy of immune deficiency conditions comprising an active principle--a peptide of the structure: H-L-Glu-L-Trp-OH and a pharmaceutically acceptable vehicle.

Abstract: A thymus-gland preparation is provided which contains polypeptides with a molecular weight of 600-6,000 Dalton and has the following composition, in percent by weight:______________________________________ polypeptides with an isoelectric point 80-90 of 3.5-6.7 polypeptides with an isoelectric point 20-10. of 7-9 and a molecular weight of 2,000-4,000 Dt ______________________________________A method for the production of the thymus-gland preparation is also provided and comprises homogenization of thymus tissue, extraction of the resulting homogenizate with a 1-10% aqueous solution of acetic acid in the presence of zinc chloride for at least 24 hours, separation of the resulting extract into a precipitate and a supernatant liquid which is treated with an organic solvent, followed by isolation of the desired product.